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WHAT THIS PAPER ADDS
 We present a novel vascular access device which allows for successful hemodialysis despite the presence of central venous stenosis
and/or occlusion. Currently, there is no other device on the market like the Hemodialysis Reliable Outﬂow (HeRO) graft. There have
been various descriptions of this device in the literature, but this manuscript offers the largest review to date on its performance in
terms of patency, interventions, and infection; which is then compared to the arteriovenous graft and tunneled dialysis catheter
literature. Additionally, this review elucidates the longest multi-patient follow up on the HeRO graft to date.a r t i c l e i n f o
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Objective: To report a multi-center experience with the novel Hemodialysis Reliable Outﬂow (HeRO)
vascular access graft.
Materials and methods: Four centers conducted a retrospective review of end stage renal disease patients
who received the HeRO device from implant to last available follow-up. Data is available on 164 patients
with an accumulated 2092.1 HeRO implant months.
Results: At 6 months, HeRO primary and secondary patency is 60% and 90.8%, respectively and at 12
months, 48.8% and 90.8%, respectively. At 24 months, HeRO had a primary patency of 42.9% and
secondary patency was 86.7%. Interventions to maintain or re-establish patency have been required in
71.3% of patients (117/164) resulting in an intervention rate of 1.5/year. Access related infections have
been reported in 4.3% patients resulting in a rate of 0.14/1000 implant days.
Conclusions: In our experience the HeRO device has performed comparably to standard AVGs and has
proven superior to TDCs in terms of patency, intervention, and infection rates when compared to the
peer-reviewed literature. As an alternative to catheter dependence as a means for hemodialysis access,
this graft could reduce the morbidity and mortality associated with TDCs and have a profound impact on
the costs associated with catheter related infections and interventions.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.viously presented in poster
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Establishing andmaintaining vascular access remains a constant
challenge for those that care for patients with end stage renal
disease (ESRD). As our patients enjoy longer lives secondary to
advances in medicine, access maintenance is becoming even more
demanding. Adequate venous outﬂow is essential in creating
a well-functioning arteriovenous (AV) access, and as outﬂowd by Elsevier Ltd. All rights reserved.
Figure 1. Illustration of HeRO components inserted via right IJV with brachial artery
inﬂow. (Courtesy of Hemosphere, Inc.).
Figure 2. Outﬂow component and ePTFE graft coupled (top), and uncoupled (bottom)
with titanium coupler visible. (Courtesy of Hemosphere, Inc.).
S.M. Gage et al. / European Journal of Vascular and Endovascular Surgery 44 (2012) 93e9994options progress centrally the daunting task of access establish-
ment becomes much more problematic and technically chal-
lenging. Eventually, adequate venous outﬂow options progress too
far centrally for placement of traditional AV access, or cease
completely secondary to central venous stenosis and/or occlusion.
When this occurs, traditional access algorithms suggest lower
extremity AV access or condemnation to tunneled dialysis catheters
(TDCs); both of which signiﬁcantly increase the patient’s risk of
developing a serious blood stream infection.2,3 In extreme cases,
exceedingly morbid and complex procedures have been described
that require median sternotomy or thoracotomy in order to
establish venous outﬂow via a right atrial anastomosis or require
insertion of destination trans lumbar or hepatic catheters.4,5
Tunneled dialysis catheter related complications, such as blood
stream infection and catheter malfunction, subject ESRD patients to
a higher likelihood of morbidity and mortality as well as more
frequent hospitalizations. Danese et al. estimated that TDC
infection-associated mortality can be as high as 34%.6 Furthermore,
the current TDC rate in the United States is estimated to be 27%.7 In
addition to this stressor to the health system and drain on
resources, these complications translate to healthcare expenditures
of an estimated one billion dollars annually.8
A novel device has been developed to meet the challenging
anatomic demands of such patients with the intent to liberate this
population from their catheter dependence. The Hemodialysis
Reliable Outﬂow (HeRO) vascular access device (Hemosphere, Inc.,
Minneapolis, MN) was made commercially available in the United
States in May 2008 after the FDA approved the device for use in
catheter dependent patients with central venous stenosis and/or
occlusion. The purpose of this study was to further evaluate the
overall performance and outcomes of the HeRO device on a larger
scale in the post-market approval phase, while also comparing its
performance to that of TDCs and conventional arteriovenous grafts
(AVGs) based on existing literature with respect to patency,
bacteremia, and intervention rates.
Materials and Methods
Study design
A retrospective review of 164 consecutive patients receiving the
HeRO device was conducted at four institutions (Duke University
Medical Center, Bamberg County Hospital, University of Miami and
Baylor Health Systems) betweenMay 2008 and February 2011. Data
was collected from time of implant to last available follow-up.
Analysis was performed on the following data points: demo-
graphics, medical co-morbidities, procedure-related adverse
events, access-related adverse events, bacteremia rates, HeRO
patency, and intervention rates. Patency and bacteremia data was
assessed at 6, 12, and 24 months. This study was approved by the
Institutional Review Board at each participating site and awaiver of
consent was granted due to its retrospective nature and de-
identiﬁcation of data.
Device description
The HeRO graft is an implantable, completely subcutaneous,
hybrid “graft-catheter” vascular access device approved for
catheter-dependent patients with limited venous outﬂow. More
speciﬁcally, the HeRO graft is reserved for those patients whose
venous outﬂow options have progressed too far centrally (proximal
to the axillary vein) to implant standard upper extremity access,
those who have developed central vein stenosis resistant to
angioplasty and/or stenting, or patients with central vein occlusion.
In those patients with complete central vein occlusion, HeRO graftscould only be implanted if their occlusions were successfully
crossed or if they had occluded around a previously placed TDC.
This device can bypass central venous stenosis and/or occlusion by
traversing the lesion endovascularly and positioning the tip of the
outﬂow component at the cavo-atrial junction or any available
large outﬂow target vein (Fig. 1). This device consists of two
components: a conventional ePTFE graft component and a silicone
venous outﬂow component connected via titanium coupler. The
graft component is a standard 6 mm internal diameter (ID) ePTFE
vascular conduit. The outﬂow component is an endolumenal, large
bore, single lumen, nitinol braid-reinforced, silicone tube with an
ID of 5 mm and OD of 19 Fr (6.3 mm), which does not require
a venous anastomosis (Fig. 2). The graft component requires 2e4
weeks of tissue incorporation, the same as is required by stan-
dard ePTFE AVGs, to allow for safe cannulation for hemodialysis.
The HeRO graft is accessed for hemodialysis in the same manner as
conventional AVGs.
Surgical implant procedure
Prior to implantation, all patients underwent a complete history
and physical exam. Adequate arterial inﬂow was assessed and
declared by physical exam. Each patient required upper extremity
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central venous system and to conﬁrm the requisite of this device.
Only patients with moderate to severe central venous stenosis and/
or occlusion received the HeRO device. All HeRO grafts were
implanted in the operating room in a hybrid fashion utilizing
a combination of both open surgical and endovascular techniques.
General endotracheal tube anesthesia was required for all HeRO
implants given the need to tunnel across the chest wall and
shoulder. The silicone outﬂow component is ﬁrst inserted into the
internal jugular, subclavian, or femoral vein via Seldinger technique
or via catheter (TDC or other central venous catheter) exchange.
Central venous angiography is used to conﬁrm proper placement of
the outﬂow component tip at the cavo-atrial junction. Once venousFigure 3. HeRO implant procedure. Left subclavian vein in-stent occlusion (1). Crossed le
component tunneled to delto-pectoral groove (4). Brachial artery exposure (5). ePTFE graft
courtesy of Hemosphere, Inc.).access is established, the distal end of the outﬂow component is
tunneled from the venous insertion site to a counter incision at the
delto-pectoral groove. Arterial exposure commences and inﬂow is
established from the artery or inﬂow conduit of choice. The ePTFE
graft component is tunneled subcutaneously from the counter
incision at the delto-pectoral groove to the arterial exposure, over
the biceps muscle, in a superﬁcial soft C-curve or large teardrop
loop (tight C) conﬁguration to provide a maximal segment for
cannulation. The two components are then coupled at the counter
incision using the titanium connector. A standard arterial anasto-
mosis is performed at the target artery to provide inﬂow for the
HeRO (Fig. 3). Please note that this is a general guideline for
straightforward, upper extremity implants. Depending on theft subclavian vein lesion (2). Outﬂow component at cavo-atrial junction (3). Outﬂow
tunneled to brachial artery exposure (images courtesy of Shawn M. Gage and photos
Table 1
HeRO recipient demographics.
Demographic % (n/N)
Agea 55.9  14.3 (162) [21e88]
Male 48.8% (79/162)
Race
Black/African American 78.3% (126/161)
White/Caucasian 13.0% (21/161)
Hispanic 8.7% (14/161)
Diabetic 46.3% (76/161)
Mean follow-up (months)a 12.8  9.1 (164) [0.07e32.9]
Deaths 17.7% (29/164)
a Mean  SD (N), [Range].
Table 2
HeRO implant speciﬁcs.
Anatomical location % (n)
Insertion side: N ¼ 139a
Right 51.8% (72)
Left 48.2% (67)
Insertion vein: N ¼ 139a
Internal jugular 59.7% (83)
Subclavian 23.7% (33)
Common femoral 6.5% (9)
Axillary 5.0% (7)
External jugular 2.9% (4)
Other 2.2% (3)
a Data only available from 3 sites.
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body, these steps can be performed in a diverse order and the
components can be connected in varying locations of the body.
Deﬁnitions
Bacteremia literature control
We used Katzman’s et al. meta-analysis of 15, prospective,
randomized controlled trials on cuffed, internal jugular vein TDCs
as our bacteremia literature control rate (2.3/1000 catheter days).9
Bacteremia rates for AVGs were calculated by Murad whose meta-
analysis reported on 83 studies, and the calculated infection rate
was 14.9%.10 Our access related infection (ARI) data will be
compared to the bacteremia data.
Patency and intervention literature control
Again, Katzman et al. conducted a meta-analysis of six retro-
spective and prospective TDC studies to generate the patency and
intervention literature controls out to 6 and 12 months.9 Primary-
assisted patency was not calculated in this study because only
one patient required an intervention to maintain primary patency.
The meta-analysis generated an overall catheter intervention rate
of 5.8 per year and primary patency at 6 and 12 months of 50% and
36%, respectively. The AVG primary patency literature control rates
at 6 and 12 months of 58% and 42% respectively, and secondary
patency at 6 and 12 months of 76% and 65% respectively, were
based on a published meta-analysis of 34 studies.11
Access related infection
Access Related Infection was deﬁned as at least one positive
blood culture following HeRO implant with at least one or more
clinical manifestations such as, fever, hypotension, peri-graft cellu-
litis, or frank graft infection requiring systemic treatment and/or
HeRO graft explantation. This differs from the Katzman study in that
their ‘bacteremia’data only took into account blood stream infection
and not speciﬁcally whether or not the HeRO graft was the culprit
based on local signs and symptoms. Also, unlike theKatzman article,
bacteremia events were not classiﬁed into separate cohorts such as
the “bridging period” or “HeRO alone period”. The ARI data in this
review takes into account all-comers from HeRO implant date to
explant, ligation, patient death, or last available follow up. The ARI
data was analyzed as a rate per 1000 days.
Patency
Primary patency is deﬁned as time from implant to ﬁrst loss of
HeRO patency. Secondary patency is deﬁned as implant time
through restoration of patency following graft thrombosis, until
ultimate graft failure and abandonment.
HeRO days
HeRO days were deﬁned as accumulated days fromHeRO implant
to earliest of explant, ligation, or death, and last follow-up visit. For
purposes of measuring the primary end point bacteremia rate, this is
comparable to the term “catheter days,” meaning days with an
indwelling catheter as commonly referred to in the catheter literature.
Statistical analysis
Continuous data were summarized using descriptive statistics
(i.e. mean, standard deviation, minimum, maximum). Categoricaldata were summarized with counts and percentages. The inter-
vention rate was calculated as the total number of interventions
reported, divided by total HeRO years. The ARI rate was calculated
as the total number of ARIs reported, divided by total HeRO days,
and then multiplied by 1000 to obtain the rate per 1000 days. Exact
Poisson 95% conﬁdence intervals (CI) were calculated for the
intervention and ARI rates. KaplaneMeier estimates and their
corresponding 95% CIs were used to summarize primary and
secondary patency at 6, 12, and 24 months post implant.
KaplaneMeier curves for freedom from loss of primary and
secondary patency were also created.Results
Demographics and implant speciﬁcs
A total of 164 patients underwent successful HeRO implantation
across 4 medical centers, resulting in an accumulation of 2092.1
HeRO months. Follow up ranged from 0.07 to 32.9 months with
a mean of 12.8. Mean agewas 55.9 with a range of 21e88 years. The
distribution of gender was nearly equal with females predominat-
ing slightly at 51.2%. The vast majority of patients (78.3%) were of
African American descent which is consistent with the renal failure
patient demographic in our region (Southeast US). During the
period of follow up, 29 patients (17%) expired (Table 1). The number
of HeROs placed was nearly equal bilaterally with 51.8% being
placed on the right. The vast majority of HeROs (59.7%) were
inserted via the internal jugular vein (IJV), although, multiple
anatomical sites were utilized in addition, including the subclavian,
common femoral, and axillary veins (Table 2).Access related infection results
ARI data was available from only 3 sites N ¼ 140, which trans-
lates to 1927.1 HeRO months follow up. Data was recorded from
implant to last available follow up. Overall, 8 ARIs occurred in 6
Table 3
HeRO patency by site.
Site Primary patencya
KM estimate [95% CI]
Secondary patencyb
KM estimate [95% CI]
Bamberg:
6 Month 51.0% [34.9e65.1] 80.1% [65.1e89.8]
12 Month 40.8% [25.7e55.4] 80.1% [65.1e89.8]
24 Month 34.9% [20.5e49.8] 80.1% [65.1e89.8]
Baylor:
6 Month 53.3% [31.7e70.9] 87.0% [64.8e95.6]
12 Month 47.4% [25.8e66.3] 87.0% [64.8e95.6]
24 Month 47.4% [25.8e66.3] 87.0% [64.8e95.6]
Duke:
6 Month 62.0% [47.6e73.4] 98.1% [87.6e99.7]
12 Month 45.1% [29.9e59.2] 98.1% [87.6e99.7]
24 Month 38.7% [21.8e55.3] 85.5% [60.1e93.8]
Miami:
6 Month 72.7% [54.1e84.8] 93.9%[77.9e98.4]
12 Month 67.9% [47.9e81.6] 93.9%[77.9e98.4]
24 Month 62.7% [41.6e77.9] 93.9%[77.9e98.4]
a No difference across sites in primary patency rates; Log-rank p-value ¼ 0.135.
b No difference across site in secondary patency rates; Log-rank p-value ¼ 0.251.
Figure 4. KaplaneMeier curve illustrating primary patency. Standard error bars at 3, 6,
9, 12, and 24 months.
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was considerably lower than the TDC bacteremia literature control
rate of 2.3/1000 catheter days (95% CI: 0.06, 0.27) and the AVG
bacteremia control rate of 14.9%.9,10
Patency and intervention
At 6 months HeRO primary patency was 60% and secondary
patency was 90.8%. HeRO primary and secondary patency at 12
months was 48.8% and 90.8%, respectively. And at 24months, HeRO
had a primary patency of 42.9% and secondary patency was 86.7%.
There was no signiﬁcant difference in terms of patency across the 4
centers (Table 3). Overall, 257 interventions to maintain or re-
establish patency occurred during 174.4 total patient years result-
ing in a HeRO intervention rate of 1.5/year (Table 4 and Figs. 4
and 5). For those patients in which secondary patency could not
be regained, another attempt at an upper body HeRO of the
contralateral limb was ﬁrst investigated. If no suitable options in
the upper body were apparent, a lower limb AVGwas considered as
the next option. And ﬁnally, if no suitable options for a lower limb
AVG were possible, the patient was then relegated to a destination
TDC via the femoral, transl umbar, or transhepatic approach.
Discussion
Since its approval in 2008 the HeRO graft has shown great
promise as a durable vascular access device. Technically, the
implant procedure has become very feasible and follows suit in theTable 4
HeRO patency, intervention, and infection data.
Variable % [95% CI]
HeRO Patencya
Primary at 6 months 60.0% [51.7, 67.3]
Secondary at 6 months 90.8% [84.9, 94.4]
Primary at 12 months 48.8% [39.9, 57.0]
Secondary at 12 months 90.8% [84.9, 94.4]
Primary at 24 months 42.9% [33.3,52.0]
Secondary at 24 months 86.7% [78.9,91.8]
HeRO intervention rateb 1.5/year [1.30, 1.67]
Access-related infectionsc,d 4.3% (6/140)
a Kaplan-Meier estimates with corresponding 95% CI.
b Rate per patient-year of follow-up; 257 events in 174.4 total patient years.
c % (n/N).
d Data only available from 3 sites.emerging world of hybrid vascular surgery. This approach to
establishing and maintaining vascular access has become abso-
lutely necessary in order to expand the number of total body
vascular access sites when the requisite for venous outﬂow is
paramount. Currently there is no other device on the market that
accomplishes what the HeRO can in terms of maintaining central
venous outﬂow. Central venous angioplasty and stenting has been
the treatment of choice for stenotic or pre-occlusive lesions to date,
but multiple reports note that this therapy has poor durability in
general; prone to rapid, recurrent re-stenosis and/or acute occlu-
sion, which has proven consistent with our observation as well.12,13
Catheter dependent patients with occlusion of the central veins
have largely been abandoned for upper body access. A few small
case reports describe a direct bypass or arteriovenous shunt to the
right atrium or central vein reconstruction to circumvent this
dilemma. Unfortunately, these operations require thoracotomy or
sternotomy which places the patient at signiﬁcant intraoperative
risk and exposes them to increased post-operative morbidity.4,5
Clinical experience with the HeRO device is growing. In a 75
patient post-market study of the HeRO device focusing on proce-
dural outcomes, an implant success rate of 100% was reported in an
access-challenged patient population.14 In September 2009, Katz-
man et al reported results of the FDA clinical trial of the HeRO
device in catheter-dependent patients. In this 36 patient evalua-
tion, at a mean 8.6 months follow up, primary patency was 38.9%
and secondary patency was 72.2%. Patency results were found to be
similar in a single center review of 41 consecutive implants
reported by Gage et al. in May of 2010.15 In that review, primary and
secondary patency at 6 months was 68.3% and 87.8%, respectively.
In this current review, we have observed the longest multi-patientFigure 5. KaplaneMeier curve illustrating secondary patency. Standard error bars at 3,
6, 9, 12, and 24 months.
Table 5
Patency comparison of published HeRO data, AVG literature, and TDC literature.
Study Current HeRO
multicenter
Gage et al. review
May 201015,a
Katzman et al.
study Sept. 20099
AVG literature11 TDC literature9
Months 6 mo 12 mo 6 mo 8.6 mo 6 mo 12 mo 6 mo 12 mo
Patency
Primary, % 60 48.8 68.3 38.9 58 42 50 36
Secondary, % 90.8 90.8 87.8 72.2 76 65 55 37
a 39 of the 41 patients in the Gage review are included in this current Multi-center review.
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patency results were reproducible in this study with 6 month
primary and secondary rates at 60% and 90.8%, respectively, and 12
month primary and secondary rates at 48.8% and 90.8%, respec-
tively (Table 5). Most impressively, however, are the patency rates
that were observed out to 24 months. These patency rates were
nearly identical to those of the 12 month data with a primary
patency rate of 42.9% and secondary patency at 86.7%.
The FDA trial and Duke University single center review, both also
evaluated intervention and bacteremia data. Interventions rates
were 2.5 and 1.38 per year, respectively, while we observed a HeRO
intervention rate of 1.5 per year in our review. This data is
comparable to the standard AVG intervention rates reported in the
peer review literature, but signiﬁcantly better than the TDC inter-
vention rate control of 5.8 per year (95% CI: 1.30, 1.67). All inter-
ventions performed in this review were done to maintain or re-
establish HeRO graft patency. HeRO mechanical and or chemical
thrombolysis was performed in an open or percutaneous fashion.
HeRO thrombectomy is performed in a similar fashion as done for
a standard AVG, and typically no more difﬁcult given the lack of
a venous anastomosis. Overall, the most common cause for HeRO
graft thrombosis to date seems to be associated with intragraft
stenosis and adherent clot as opposed to the titanium coupler
connection site, which had been generally suspected to be the most
likely cause.16 Bacteremia data from the FDA trial and from Duke’s
single center review were similar with rates of 0.70 and 1.29 per
1000 days, respectively. However, in the current review we
observed an ARI rate of 0.14 per 1000 implant days which is much
lower than the previous HeRO data, but signiﬁcantly lower than the
TDC control data of 2.3 per 1000 catheter days (Table 6). Of those
patients with an infection, ﬁve required complete explantation of
the HeRO graft and 2 others only required excision and replace-
ment of an isolated infected segment of the ePTFE graft. One subject
developed an infection while the device was not in use; after it had
thrombosed and was abandoned.
Only two patients (1.4%) developed clinically signiﬁcant steal
syndrome requiring removal of the HeRO graft. One patient
required exchange of the HeRO for a TDC as that was their last
viable site for access. The second patient required patch angioplasty
of the brachial artery at the time of HeRO graft explantation. A
commonmisconception is that the HeRO device has a propensity to
cause steal syndrome given its lack of a venous anastomosis, and
thus unopposed outﬂow and high output. However, in our clinicalTable 6
Bacteremia and intervention comparison of published HeRO data, AVG literature,
and TDC literature.
Study Bacteremia rate
per 1000 days
Intervention
rate per year
Current HeRO Multicenter 0.14 1.5
Gage et al. Review May 201015 1.29 1.38
Katzman et al. Study Sept. 20099 0.7 2.5
AVG Literature Control9 NAa 1.6e2.4
TDC Literature Control9 2.3 5.8
a Information not available.experience this has not been observed. We speculate that the low
observed clinically signiﬁcant steal rate is a function of the intrinsic
hemodynamics of the device where both the length of the device
(roughly twice the length of conventional grafts) and the diameter
(5 mm ID outﬂow component) contribute to reduce the ﬂow and
preserve perfusion to the hand.
There were no intraoperative deaths but four were reported
within the immediate 2 week postoperative period. One patient
died of suspected right heart overload 1 week post HeRO implant
and another died of a massive CVA at 2 weeks. The third patient
diedwhile still in the hospital 12 days post operatively secondary to
a massive GI bleed. The fourth patient died of ARDS related respi-
ratory failure ultimately as a result of a severe pulmonary effusion.
This occurred secondary to the exchange of her long-term fenes-
trated tracheostomy (in the setting of intraoperative systemic
heparinization) for the use of an alternative tracheostomy, which
was thought to be more favorable for use with mechanical venti-
lation to provide general anesthesia. This led to a severe pulmonary
effusion, and ultimately, death. None of these deaths were thought
to be directly related to the surgical implantation of the HeRO
device. Overall, 29 patients (17%) died during the mean follow up
period of 15.4 months, attesting to the extreme morbidity of the
end stage vascular access patients with central venous pathology.
In the post-market approval phase the HeRO device has per-
formed comparably to standard AVGs as reported in the peer
review literature. This retrospective evaluation of the HeRO graft in
164 patients represents the largest dataset available to-date on its
performance and supports ﬁndings reported previously in a smaller
(n ¼ 36), prospective study of TDC-dependent patients and the
Duke retrospective evaluation (n ¼ 41). In our experience its
performance has proven superior to tunneled dialysis catheters in
terms of patency, intervention, and infection rates when compared
to the peer reviewed literature.9 Additionally, we have found the
HeRO graft to perform similarly, in terms of patency, when
compared to the AVG peer reviewed literature.11 This device has
shown great promise as an alternative to catheter dependence as
a means for durable, permanent hemodialysis access and as a result
could reduce the morbidity and mortality associated with TDCs.
Furthermore, use of this device could have a positive impact on
costs associated with catheter related infections and interventions.
We realize the weaknesses that comparing data to historical review
articles impose, nonetheless to date this serves as the best control
statistics available. These preliminary results are favorable;
however, data from additional prospective, randomized trials could
add further clarity on the HeRO’s performance and prove to make
this device a permanent ﬁxture in the vascular access algorithm.
Of the 75 patients in the Katzman review, 18 were included in
this current Multi-center review.
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